Alexey Berezhnoy
Director, Immunology Zymeworks
Dr. Berezhnoy heading department of immunology in Zymeworks from 2024. Prior to that, he led development of conditional therapeutics for oncology at CytomX Therapeutics. His industrial career started in MacroGenics where he performed preclinical and early clinical work with bispecific molecules for IO and AIID.
Seminars
Thursday 11th June 2026
Outlining ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation
9:30 am
- Discuss how ZW1528 high-affinity binding to IL-4Ra and IL-33 mediates potent blockade of IL-4, IL-13, and IL-33 pathways, and drives in vitro inhibition of type 2 and non-type 2 responses in primary immune cells of COPD patients
- Demonstrate that ZW1528 significantly reduces both systemic and local lung inflammation in mice with humanized IL-4/IL-4Ra
- Review ZW152’s good tolerability and favorable pharmacokinetics in the NHP and biomarkers of target blockade
- Unveil how these findings validate the rational design of ZW1528 and support its therapeutic potential across a range of airway inflammatory conditions
